



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/529,059	12/14/2005	William Marshall Stark	056646-5024	2559
9629 7590 02/17/2009 MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW WASHINGTON, DC 20004				
EXAMINER				
CHOWDHURY, IQBAL HOSSAIN				
ART UNIT		PAPER NUMBER		
1652				
MAIL DATE		DELIVERY MODE		
02/17/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/529,059

Applicant(s)

STARK ET AL.

Examiner

IQBAL H. CHOWDHURY

Art Unit

1652

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 January 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 3, 4, 46, 47, 52, 54-59 and 67 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☒ Claim(s) 4, 46, 47, 52, 54, 57-59 and 67 is/are allowed.
- 6) ☒ Claim(s) 3, 55-56 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
- Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DTAILED ACTION

Claims 3-4, 46-47, 52, 54-59 and 67 are currently pending.

In response to a previous Office action, a final action (mailed on July 10, 2008), Applicants filed a response on January 12, 2009 and amended claims 46, 54, 58 and 67 and canceled claims 1-2, 7-10, 12-14, 18-23, 28-42, 53 and 68 is acknowledged.

Claims 3-4, 46-47, 52, 54-59 and 67 are under consideration.

Applicants' arguments filed on January 12, 2009, have been fully considered but are not deemed persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Claim objection

Claim 59 is objected to in the recitation "yS resolvase", 3 resolvase", "15607 resolvase", or "OC31 resolvase", which should be "γδ resolvase", β resolvase", "IS607 resolvase", or "ΦC31 resolvase". Appropriate corrections are required.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 3 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Arnold et al. (Mutants of Tn3 resolvase which do not require accessory binding sites for recombination activity, EMBO J. 1999 Mar 1; 18(5): 1407-14, see IDS).

Arnold et al. teach a mutant of serine recombinase Tn3 resolvase comprising a mutation at position G101 of SEQ ID NO: 2, wherein the mutation is G101S (see abstract, Page 1403, column 2, line 2), which is 100% identical to SEQ ID NO: 2 of the instant application because applicants used the same gene in a plasmid for mutagenesis (see Materials and Methods, page 30, paragraph 2 of the specification). Arnold et al. also teach catalytic domain (page 1409, column 2, line 4) and DNA binding site of Tn3 resolvase, which contains a DNA binding domain (Abstract and Fig. 1). Besides, all serine recombinases comprise N-terminal catalytic domain and C-terminal DNA binding domain (see for example; Smith et al. 2002). Thus, Tn3 resolvase of Arnold et al. inherently comprise DNA binding domain. Therefore, Arnold et al. anticipate claims 3 and 55-56.

Conclusion

Status of the claims:

Claims 3-4, 46-47, 52, 54-59 and 67 are pending.

Claim 4 and 46-47, 52, 54, 57-59 and 67 are allowed.

Claims 3 and 55-56 are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Iqbal Chowdhury whose telephone number is 571-272-8137. The examiner can normally be reached on 9:00-5:00 PM.

Art Unit: 1652

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat T. Nashed can be reached on 571-272-0934. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Iqbal Chowdhury, Patent Examiner
Art Unit 1652 (Recombinant Enzymes)
US Patent and Trademark Office
Rm. REM 2B69, Mail Box. 2C70
Ph. (571)-272-8137, Fax. (571)-273-8137

/Nashaat T. Nashed/
Supervisory Patent Examiner, Art Unit 1652